Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vacuna inactivada porcina is a polyvalent inactivated veterinary vaccine developed by FARVET for the prevention of major respiratory and enteric diseases in swine. The vaccine formulation includes inactivated bacterial antigens from *Actinobacillus pleuropneumoniae* (serotypes 1, 5, and 7), *Pasteurella multocida* (types A and D), *Haemophilus parasuis* (serotypes 1, 4, and 5), *Salmonella choleraesuis*, *Salmonella typhimurium*, and *Erysipelothrix rhusiopathiae*. By presenting these inactivated pathogens to the porcine immune system, the vaccine stimulates the production of specific antibodies and primes cellular immunity, providing protection against pleuropneumonia, pasteurellosis, Glässer's disease, salmonellosis, and swine erysipelas. It is typically administered to piglets and sows to reduce morbidity and mortality associated with these infections in commercial swine operations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vacuna inactivada porcina.